PRELIMINARY PROGRAM
PRELIMINARY PROGRAM
TABLE OF CONTENTS About the DIA 2019 Global Annual Meeting......................................................................................................3 DIA Leadership........................................................................................................................................................... 4 Keynote Speaker ....................................................................................................................................................... 5 Honorary Co-Chairs.................................................................................................................................................. 5 Key Tracks ................................................................................................................................................................... 6 Schedule At-A-Glance ............................................................................................................................................. 8 DIA 2019 is a “Patients Included” Event............................................................................................................. 9 DIA 2018 Global Annual Meeting By the Numbers.........................................................................................10
DIAglobal.org
2
PRELIMINARY PROGRAM
ABOUT THE DIA 2019 GLOBAL ANNUAL MEETING DIA, founded as the Drug Information Association, has provided a global, yet neutral stage, for collaboration to address healthcare challenges for more than 50 years. DIA’s Global Annual Meeting (DIA 2019) gathers stakeholders from across the world to openly share knowledge, generating insights beyond boundaries to advance innovation in healthcare product development and lifecycle management globally. Everyone passionate about working at the global intersection of science, healthcare, and regulation come together at DIA. No barriers, just dialogue among thought leaders and regulators who may not otherwise connect. As the largest, longest-running event in the life sciences industry, this gathering is designed to foster the international exchange of actionable insights to improve health globally through the advancement of lifesaving medicines and technologies. The DIA 2019 Global Annual Meeting will host more than 7,000 professionals in the pharmaceutical, biotechnology, and medical device communities from more than 50 countries around the globe and 400+ exhibiting companies. The goal of the DIA 2019 Global Annual Meeting is to provide you and your team with a rare opportunity to build on what you already know in the development of new therapies and accelerate efforts to enhance health and well-being.
REGISTER TODAY DIAglobal.org
3
PRELIMINARY PROGRAM
DIA LEADERSHIP Executive Leadership Team • Barbara Lopez Kunz, MS, Global Chief Executive • Bayard G. Gardineer, MS, CPA, Chief Financial Officer • Bill Allman, Chief Digital Officer • Timothy Hess, Global Director of IT • Thomas Bols, Senior Vice President and Managing Director, DIA EMEA
• Sudip S. Parikh, PhD, Senior Vice President and Managing Director, DIA Americas • Akio Uemura, PhD, Senior Vice President and Managing Director, DIA Japan • Carol Zhu, RPh, MBA, Senior Vice President and Managing Director, DIA Greater China
• Youngshin Lee, PhD, Senior Vice President and Managing Director, DIA South Korea and ASEAN
Board of Directors • Joseph Scheeren, PharmD, Chair DIA, President and CEO, Critical Path Institute
• Judith Ng-Cashin, MD, Director DIA, Chief Medical Officer, AoBiome
• John A. Roberts, MBA, Immediate Past Chair DIA, President and Chief Executive Officer, Cancer Genetics
• Michael Romano, Director DIA, Partner - Life Science Industry Practice Group, RSM US
• Rebecca Veremeulen, RPh, Chair-Elect DIA, Senior Director, BioOncology Medical Science Liaisons, Genentech, A Member of the Roche Group
• Michael Rosenblatt, MD, Director DIA, Chief Medical Officer, Flagship Pioneering
• Jeffrey S. Payne, CPA, CGMA, Chief Financial Officer, ReMed • Barbara Lopez Kunz, MS, Global Chief Executive, DIA • Andrzej Czarnecki, MD, PhD, DSc, Director DIA, Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety, Eli Lilly and Company, Ltd., UK • Angelika Joos, MPharm, Director DIA, Executive Director, Global Regulatory Policy, Merck Sharp and Dohme (Europe) Inc., Belgium
• Jonathan Sheldon, PhD, Director DIA, Senior Vice President, Head Bioinformatics Business Area, QIAGEN, United Kingdom • Kihito Takahashi, PhD, MD, Director DIA, Vice President and Director, Japan Development, GlaxoSmithKline K.K., Japan • Lingshi Tan, PhD, Director DIA, Founder, Chairman, and CEO, dMed Company Limited • Cynthia L. Verst, PharmD, MS, Director DIA, President, R&D Design and Delivery Innovation, IQVIA
Advisory Councils • Yoshiaki Uyama, PhD, Chair, Council of Regulators Liaison Committee, Japan Pharmaceuticals and Medical Devices Agency Liaison to DIA Board • Peter Bachmann, PhD, Council of Regulators Liaison Committee, European Regulatory Network Liaison to the DIA Board • Gerald J. Dal Pan, MD, Council of Regulators Liaison Committee, US Food and Drug Administration Liaison to the DIA Board • Petra Dörr, PhD, Council of Regulators, Swissmedic Liaison to the DIA Board • Jeong Mi Kim, Council of Regulators, Ministry of Food and Drug Safety Liaison to the DIA Board
• Celia Lourenco, PhD, Council of Regulators, Health Canada Liaison to the DIA Board • Mike Ward, Council of Regulators, World Health Organization Liaison to the DIA Board • Stephanie Y. Crawford, PhD, MPH, Chair, Regional Advisory Council, Americas • Jingsong Wang, MD, PhD, Chair, Regional Advisory Council, China • Maren von Fritschen, PhD, Chair, Regional Advisory Council, EMEA • Kazumichi Kobayashi, RPh, Chair, Regional Advisory Council, Japan
• Yee Hoo Looi, PhD, Council of Regulators, Health Sciences Authority Singapore Liaison to the DIA Board
DIAglobal.org
4
PRELIMINARY PROGRAM
KEYNOTE SPEAKER Gary H. Gibbons, MD, Director, National Heart, Lung, and Blood Institute (NHLBI), NIH Gary H. Gibbons, MD, is Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), where he oversees the third largest institute at the NIH, with an annual budget of approximately $3 billion and a staff of nearly 2,100 federal employees, contractors, and volunteers. NHLBI provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so they can live longer, and more fulfilling lives. Since being named Director of the NHLBI, Dr. Gibbons has enhanced the NHLBI investment in fundamental discovery science, steadily increasing the payline and number of awards for established and early stage investigators. His commitment to nurturing the next generation of scientists is manifest in expanded funding for career development and loan repayment awards as well as initiatives to facilitate the transition to independent research awards. Dr. Gibbons provides leadership to advance several NIH initiatives and has made many scientific contributions in the fields of vascular biology, genomic medicine, and the pathogenesis of vascular diseases. His research focuses on investigating the relationships between clinical phenotypes, behavior, molecular interactions, and social determinants on gene expression and their contribution to cardiovascular disease. Dr. Gibbons has received several patents for innovations derived from his research in the fields of vascular biology and the pathogenesis of vascular diseases. Throughout his career, Dr. Gibbons has received numerous honors, including election to the Institute of Medicine of the National Academies of Sciences; selection as a Robert Wood Johnson Foundation Minority Faculty Development Awardee; selection as a Pew Foundation Biomedical Scholar; and recognition as an Established Investigator of the American Heart Association (AHA).
HONORARY CO-CHAIRS Professor Guido Rasi, MD, Executive Director, European Medicines Agency (EMA), European Union Professor Guido Rasi began his second term as Executive Director of the EMA on November 16, 2015. From November 2014 to mid-November 2015, Professor Rasi served as EMA’s Principal Adviser in Charge of Strategy. From November 2011 to November 2014 he was the Executive Director of EMA and a member of its Management Board in the three years prior to this. Professor Rasi holds a degree in medicine and surgery, with specializations in internal medicine, allergology, and clinical immunology, from the University of Rome. He is also an author of more than 100 scientific publications.
Joanne Waldstreicher, MD, Chief Medical Officer, Johnson & Johnson In Joanne’s current role with Johnson & Johnson, she has oversight across pharmaceuticals, devices, and consumer products for safety, epidemiology, clinical and regulatory operations transformation, collaborations on ethical science, and technology and R&D policies, including those related to clinical trial transparency and compassionate access. She chairs the R&D Development Pipeline Review Committee for The Janssen Pharmaceutical Companies of Johnson & Johnson, and supports the Medical Devices and Consumer Development Committees. Joanne is also a faculty affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine.
DIAglobal.org
5
PRELIMINARY PROGRAM
KEY TRACKS TRACK
1
Clinical Safety and Pharmacovigilance This track, with the overarching theme, Big Data – How to Address and Relevance, has sessions providing an overview of the global regulatory environment in the field of clinical safety and pharmacovigilance for medical products (biopharmaceutical products and medical devices), with a focus on pragmatic approaches to protecting patient safety and incorporating the patient voice into the complex and evolving pharmacovigilance ecosystem.
Clinical Trials and Clinical Operations TRACK
2
This track covers clinical research development and operations. Sessions explore current and innovative methods to: • Evaluate technology advances/systems to support clinical research programs and integrate cross-functional management • Optimize clinical trial enrollment and novel techniques for subject retention • Evaluate the clinical utility and endpoint development with the use of mobile/digital technology • Identify clinical questions and gaps resulting in barriers to efficient clinical research development/ management • Review optimal clinical operations management structures in small, medium, and large companies
Data and Data Standards TRACK
3
The overarching themes of this track are Navigating Data and Standards in a Big Data World, and Explosion of Technology and the Change to the Role of the Data Professional. With multiple sessions specific to Data and Data Standards, this track will appeal to a broad audience as it addresses the data topic from the perspectives of: • Sources, standards, quality, handling, and regulatory requirements • Current and emerging applications of data
Medical Affairs and Scientific Communication TRACK
4
This track will share insights from medical affairs professionals and medical writers across the globe. Sessions within the track will address necessary skills and best practices for working cross functionally and compliantly within medical affairs, medical information, and scientific communication.
Patient Engagement TRACK
5
This track is themed, Operationalizing Patient Engagement, and Concepts of Meaningful Patient Engagement. It will address meaningful patient engagement in medical product development, from early product development, and approval, through maintenance phases. It focuses on important questions for all stakeholders, including: • How do we meaningfully engage patients and incorporate their voices into decision-making throughout the medical product lifecycle? • How do we become truly patient- (and people-) centric in our approach? • How do we operationalize patient-centric approaches in our day-to-day work?
Preclinical Development and Early-Phase Clinical Research TRACK
6
Preclinical and early-phase clinical research provide initial safety, tolerability, and efficacy data for new drugs. This track focuses on topics ranging from early-stage compound selection, PK, and safety considerations for both drugs and biologics, as well as dosing strategies to data integrity for proper downstream decision-making.
DIAglobal.org
6
PRELIMINARY PROGRAM
TRACK
7
Project Management and Strategic Planning This track will illustrate best practices to improve project and program execution, strategic planning, and portfolio management, as well as how to collaborate more effectively with internal and external stakeholders to achieve project and program objectives.
R&D Quality and Compliance TRACK
8
TRACK
9
This track is composed of a plethora of sessions and is themed, End-to-End Clinical Quality – Quality Management Systems. It provides a comprehensive view of the quality landscape across the preclinical, clinical, and pharmacovigilance domains. The track focuses on innovative and risk-proportionate approaches to managing quality that are appropriate to an evolving development paradigm and in a global context.
Regulatory This track is composed of sessions addressing global laws, regulations, guidelines, and guidances that govern prescription biopharmaceutical and device product development, approval, and maintenance. Representatives from FDA, EMA, PMDA, MHRA, BfArM, and ICMRA authorities, and other regulatory experts will provide global updates, insights, and discussion on current issues, opportunities, and challenges through interactive forums. Themes include, Global Regulatory Changes and Impact on Global Development Strategies, Global Harmonization/ Convergence and Impact on Drug Development, Advances and Innovations to Improve the Practice of Regulatory Affairs, and Regulatory Hot Topics.
Regulatory CMC and Product Quality TRACK
10
With themes in CMC, Product Quality, New Technology and Innovation, FDA Initiatives, and International Harmonization, this track spans from the scientific understanding gained through product and process development to lifecycle expectations for Global Regulatory CMC submissions, CGMP, and Quality Systems. Sessions will address the increasing regulatory complexity of development and manufacturing for worldwide markets, accelerated development timelines, new technologies, emerging regulations, and increased scrutiny of manufacturing operations and data.
Statistics TRACK
11
The theme of this track is, The Role of Statistics in Realizing the Goals of the 21st Century Cures Act and the PDUFA VI Commitments. With various sessions, the Statistics track will focus on topics of theoretical and practical interest to statisticians and clinical trialists who work with medical products, including pharmaceuticals, biologics and biosimilars, combination products and devices, and generics throughout their lifecycle.
Value and Access TRACK
12
The healthcare landscape is evolving into one assessed on value, and there is a need to understand the impact of this movement on all stakeholders – providers, payers, biopharma, and ultimately patients. The Value and Access track will bring together global regulators, industry leaders, patients, and payers who will facilitate discussions and address questions such as: • What information and evidence is being used to define value? • Who is making or influencing access decisions? • How can real world data be leveraged to drive access to medicines?
TRACK
13
Professional Development The Professional Education and Development track focuses its content on topics that improve and support ongoing personal growth for career and team success. This broad category includes: interpersonal skills, soft skills, leadership, goal-setting, life-long learning, career transitions (career growth, lateral career transitions, and entrepreneurship), social media/new media, and self-awareness to assess strengths and gaps.
DIAglobal.org
7
PRELIMINARY PROGRAM Preliminary Schedule At-A-Glance
DIAglobal.org/DIA2019
SCHEDULE AT-A-GLANCE SATURDAY, JUNE 22
As of 1/24/2019. Schedule subject to change.
9:15-10:30am
Registration Hours 8:00am-5:00pm
Exhibitor Registration
SUNDAY, JUNE 23
10:30-11:30am
Educational Tracks
11:30am-1:30pm
Luncheon Service
11:45am-2:00pm
Innovation Theater Presentations (Exhibit Hall) Content Hub (Sails Pavilion) Engage and Exchange Sessions (Exhibit Hall) Professional Poster Session and Oral Presentations (Exhibit Hall)
2:00-3:15pm
Educational Tracks Community Rounds (Sails Pavilion) Engage and Exchange Session (Exhibit Hall)
3:15-4:15pm
Refreshment Break (Exhibit Hall) Innovation Theater Presentations (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Content Hub and Community Rounds (Sails Pavilion) Professional Poster Session (Exhibit Hall)
4:15-5:30pm
Educational Tracks Community Rounds (Sails Pavilion)
Registration Hours 8:00-9:00am
Registration for Full Day and Morning Preconference Short Courses*
8:00am-6:00pm
Exhibitor Registration
12:30-6:00pm
Registration for Afternoon Preconference Short Courses*, Conference Attendees, and Speakers
Schedule 9:00am-12:30pm
Half Day Morning Preconference Short Courses*
9:00am-5:00pm
Full Day Preconference Short Courses*
11:00am-12:30pm
Student and Emerging Professional Forum
1:30-5:00pm
Half Day Afternoon Preconference Short Courses*
2:30-5:00pm
Professional Development Sessions
*Space is limited for Preconference Short Courses. Onsite Registration is available, but not guaranteed.
MONDAY, JUNE 24 Registration Hours 7:00am-6:00pm
Attendee, Speaker, and Exhibitor Registration
Schedule 6:30-7:30am
CISCRP Medical Heroes Appreciation 5K
7:30-8:30am
Coffee and Light Refreshments
7:00-7:45am
Annual Meeting Orientation
8:00-10:00am
Opening Plenary, Keynote Address, and DIAmond Session
10:00am-6:00pm
Exhibit Hall Open Student Posters Open (Exhibit Hall)
10:00-11:00am
Coffee Break (Exhibit Hall) Innovation Theater Presentations (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Content Hub (Sails Pavilion) Student Poster Session and Oral Presentations (Exhibit Hall)
11:00am-12:00pm
Educational Tracks
12:00-2:00pm
Luncheon Service
12:15-2:15pm
Student Poster Session and Oral Presentations (Exhibit Hall) Innovation Theater Presentations (Exhibit Hall) Engage and Exchange Sessions (Exhibit Hall) Content Hub and Community Rounds (Sails Pavilion)
2:15-3:15pm
Educational Tracks
3:30-4:30pm
Educational Tracks
4:30-6:00pm
Opening Reception (Exhibit Hall) Innovation Theater Presentations (Exhibit Hall) Student Poster Session and Oral Presentations (Exhibit Hall) Engage and Exchange (Exhibit Hall)
TUESDAY, JUNE 25
Coffee Break (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Content Hub and Community Rounds (Sails Pavilion) Innovation Theater Presentations (Exhibit Hall)
WEDNESDAY, JUNE 26 Registration Hours 7:00am-5:15pm
Attendee, Speaker, and Exhibitor Registration
Schedule 7:00-8:00am
Coffee and Light Refreshments
8:00-9:15am
Educational Tracks Community Rounds (Sails Pavilion)
9:00am-4:00pm
Exhibit Hall Open Professional Posters Open (Exhibit Hall)
9:15-10:30am
Coffee Break (Exhibit Hall) Content Hub and Community Rounds (Sails Pavilion) Innovation Theater Presentations (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Professional Poster Session (Exhibit Hall)
10:30-11:30am
Educational Tracks
11:30am-1:30pm
Luncheon Service
11:45am-2:00pm
Content Hub and Community Rounds (Sails Pavilion) Innovation Theater Presentations (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Professional Poster Session and Oral Presentations (Exhibit Hall)
2:00-3:15pm
Educational Tracks Engage and Exchange Sessions (Exhibit Hall) Content Hub (Sails Pavilion)
3:15-4:15pm
Refreshment Break (Exhibit Hall) Engage and Exchange Session (Exhibit Hall) Content Hub and Community Rounds (Sails Pavilion) Professional Poster Session (Exhibit Hall) Innovation Theater Presentations (Exhibit Hall)
4:15-5:30pm
Educational Tracks
THURSDAY, JUNE 27 Registration Hours 8:00-11:00am
Attendee and Speaker Registration
Registration Hours
Schedule
7:00am-5:15pm
8:00-9:00am
Coffee and Light Refreshments Content Hub and Community Rounds (Sails Pavilion)
9:00-10:15am
Educational Tracks
Attendee, Speaker, and Exhibitor Registration
Schedule 7:00-8:00am
Coffee and Light Refreshments
10:15-10:45am
Coffee Break
8:00-9:15am
Educational Tracks
10:45am-12:00pm
FDA Town Hall
9:00am-5:00pm
Exhibit Hall Open
9:00am-4:00pm
Professional Posters Open (Exhibit Hall)
DIAglobal.org
8
PRELIMINARY PROGRAM
DIA 2019 IS A “PATIENTS INCLUDED” EVENT The DIA 2019 Global Annual Meeting is “Patients Included.” This means that we are committed to incorporating the experience of patients as experts in living with their condition while ensuring they are neither excluded nor exploited. For more information, visit the Patients Included website. DIA and the Global Annual Meeting Program Committee have assessed that the program successfully meets all five of the Patients Included charter clauses: Patients or caregivers with experience relevant to the conference’s central theme actively participate in the design and planning of the event, including the selection of themes, topics, and speakers. • The DIA 2019 program agenda has been structured to incorporate the patient perspective within a dedicated Patient Engagement Track. The Program Committee includes patient representatives, who have responsibility for building the Patient Engagement track, advising on appropriate inclusion of patient perspectives in sessions throughout all 13 educational tracks, and serving as resources to identify qualified patient speakers. Patients or caregivers with experience of the issues addressed by the event participate in its delivery and appear in its physical audience. • Patients and patient partners with experience or interest in furthering the impact of their involvement in medical product development are featured as speakers, panelists, and discussants throughout the program. • The Patient Partners speaker initiative assists the Program Committee and session developers with finding the right patient/patient partner to speak in the program. Travel and accommodation expenses for patients or carers participating in the advertised program are paid in full, in advance. Scholarships are provided by the meeting organizers to allow patients or carers affected by the relevant issues to attend as delegates. • As speakers, patients invited to speak in sessions will receive a speaker support package to include: registration, travel (when booked through DIA’s travel agent), hotel accommodation (room and tax, when booked through DIA’s housing partner), and per diem for additional expenses. The number of hotel nights and per diem days will depend on the number of speaking assignments (on average up to 2-4 nights are covered by DIA). Registration, travel, and hotel are paid in advance. • DIA facilitates the attendance of patients or patient partners at the DIA 2019 Global Annual Meeting through the Patient Scholars program. • In addition, DIA 2019 offers a special registration fee for patients and patient organization representatives of $250 if registered by June 6. After June 6, the standard patient registration rate of $400 will apply. Access the Patient Registration Form. The disability requirements of participants are accommodated. All applicable sessions, breakouts, ancillary meetings, and other program elements are open to patient delegates. • DIA 2019 will be held at the San Diego Convention Center, 111 W Harbor Drive, San Diego, CA. The facility features accessible entrances, registration and open areas, meeting rooms, parking, and provides assistive devices. In addition to the Convention Center, DIA has reserved sleeping room blocks at special conference rates in hotels surrounding the convention center. A complete list of hotels can be viewed here. For specific questions, please contact the hotel directly. Access for virtual participants is facilitated, with free streaming video provided online wherever possible. • The hashtag #DIA2019 will be actively promoted prior to and during the event across social media platforms so participants, as well as those unable to attend the event, can join the conversation and discuss presentations and key takeaways. • DIA will post speaker presentations to the DIA website prior to the conference and for six months after the conference for viewing and downloading by attendees. • DIA is exploring the possibilities of audio-recording key panel discussions for wider distribution post conference.
DIAglobal.org
9
PRELIMINARY PROGRAM
DIA 2018 GLOBAL ANNUAL MEETING BY THE NUMBERS
7,000
The highest attended Global Annual Meeting in the last
Global Attendees
7
400
years
12
57
Countries Represented
650+
Speakers from 21 Countries
Government representatives across 46 agencies in 20 countries including CFDA, FDA, EMA, and PMDA
Tracks
Clinical Safety and Pharmacovigilance
Project Management and Strategic Planning
Clinical Trials and Clinical Operations
R&D Quality and Compliance
Data and Data Standards
Regulatory
Medical Affairs and Scientific Communication
Regulatory CMC and Product Quality
Patient Engagement
Statistics
Preclinical Development and Early-Phase Clinical Research
Value and Access
250+ Educational Sessions
DIAmond Sessions
6
Different Educational Formats
Concurrent Educational Sessions Content Hubs Engage and Exchange Innovation Theaters Community Round Tables
DIAglobal.org
10
SAN DIEGO | JUNE 23-27
DIAglobal.org/DIA2019 Attendee Registration Form
Register online at DIAglobal.org/DIA2019. Online registration is not available to Speakers or Exhibitors. For Speakers and Exhibitors registration information, Speakers contact: AnnualMeetingProgram@DIAglobal.org and Exhibitors contact: Americas.Exhibits@DIAglobal.org. All registrations received at the DIA office in Horsham, PA, USA by 5:00PM ET on May 10, 2019 will be included in the Advance Registration Attendee List. TOTAL PAYMENT DUE Include all applicable fees
PRECONFERENCE SHORT COURSES Visit DIAGlobal.org/DIA2019ShortCourses for topics and fees. Space is limited and preregistration is encouraged. Please indicate the short course # and fee. Short Course # _______ Fee _________
STANDARD ATTENDEE RATES
Member
$1,379 $1,399 $1,599 $1,799
DISCOUNT CHARITABLE NONPROFIT/ACADEMIA RATES*
$1,789 $1,829 $1,929 $2,029
Member
Nonmember**
$1,239 $1,269 $1,349 $1,419
DISCOUNT GOVERNMENT RATES*
Member
Register by January 9, 2019 Register by February 20, 2019 Register by June 5, 2019 Register after June 5, 2019
$589 $609 $659 $719
VISA
Nonmember**
$979 $999 $1,079 $1,149
Register by January 9, 2019 Register by February 20, 2019 Register by June 5, 2019 Register after June 5, 2019
PAYMENT OPTIONS: Register online at DIAglobal.org/DIA2019 or by: CREDIT CARD: Complete this form and fax to +1.215.442.6199 or email to CustomerService@DIAglobal.org. Non-U.S. credit card payment is subject to the currency conversion rate at the time of the charge.
Short Course # _______ Fee _________ Subtotal ___________
Register by January 9, 2019 Register by February 20, 2019 Register by June 5, 2019 Register after June 5, 2019
Nonmember**
$859 $879 $929 $979
CHECK: Drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc., 800 Enterprise Road, Suite 200, Horsham, PA 19044, USA. Please include a copy of this registration form to facilitate identification of attendee. BANK TRANSFER: Upon completion of your registration, DIA will send an email to the address on the form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name, company, and Event #19001 must be included on the transfer document to ensure payment to your account. By signing below I confirm I agree with DIA’s Terms and Conditions of booking. These are available on page two of the registration form, or online under the main event Signature _______________________________________________________________
Position
Nonmember**
$1,179 $1,209 $1,279 $1,359
Indicate which day you plan to attend. MON, June 24
TUES, June 25
WED, June 26
THURS, June 27
Exp Date ___________________________________
Signature _______________________________________________________________
ONE DAY REGISTRATION RATES
$919 $939 $989 $1,039
AMEX
Name (printed) _________________________________________________________
Last Name
Member
MC
Card # ________________________________________________________________
*Discount rates are subject to eligibility requirements. Identification and proof of eligibility will be required on site. Failure to provide proof of eligibility/ID upon request will require paying the higher standard registration fee.
Register by January 9, 2019 Register by February 20, 2019 Register by June 5, 2019 Register after June 5, 2019
$
First Name
M.I.
Dr.
Mr. Ms.
Degree
Company Mailing Address (as required for postal delivery to your location) Mail Stop
** DIA MEMBERSHIP All nonmember fees include a one year DIA membership, at no additional cost. Explore membership benefits at DIAglobal.org/Membership.
City
State
DIA membership will renew automatically at the end of the complimentary membership term, at the then current membership rates. You may cancel automatic membership renewal at any time by accessing your account online at DIAglobal.org. If you would like to decline complimentary membership, please indicate your preference below.
Zip/Postal Code
Country
Telephone Number
Twitter Handle
I would like to decline a one year complimentary DIA membership.
STUDENT AND PATIENT RATES AVAILABLE
Email (required for confirmation)
Contact AnnualMeetingProgram@DIAglobal.org for eligibility requirements and an application form.
CANCELLATION POLICY: All cancellations must be received in writing at DIA’s office by 5:00PM ET, May 24, 2019. If you do not cancel by May 24, 2019 and do not attend, you are responsible for the full applicable fee. Registrants are responsible for cancelling their airline and hotel reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify CustomerService@DIAglobal.org of any such substitutions as soon as possible. Substitute registrants will be responsible for the nonmember fee, if applicable. DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel, or other costs incurred by registrants. Speakers and program agenda are subject to change. REFUND POLICY: Cancellations received in writing by CustomerService@DIAglobal.org ON or BEFORE MAY 24, 2019 will be processed as follows: Full Meeting and One Day Registration Cancellation • Registration fee paid minus $200 = Refund Amount Short Course Registration Cancellation • Registration fee paid minus $200 = Refund Amount Cancelling any portion of your program registration will void any multiple purchase discounts that may have been applied.
Exhibit Hall Access: Your meeting registration includes access to the Exhibit Hall on Monday—Wednesday when the Hall is open. DIA does not allow access to the Exhibit Hall to anyone under the age of 18. Participants with Disabilities: DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Email AnnualMeetingProgram@DIAglobal.org to indicate your needs. Photography Policy: By attending the DIA 2019 Global Annual Meeting you give permission for images of you, captured during the conference through video, photo, and/or digital camera, to be used by DIA in promotional materials, publications, and website and waive any and all rights including, but not limited to compensation or ownership.
PRELIMINARY PROGRAM
DIAglobal.org/DIA2019 REGISTER NOW DIAglobal.org
12